Cellular immunity against SARS-CoV-2 is an important component of the immune response to the virus. At present, two such tests based on interferon-gamma release (interferon-γ release assays, IGRAs) are available-Quan-T-Cell SARS-CoV-2 by EUROIMMUN and T-SPOT.COVID by Oxford Immunotec. In this paper, we compared the results of these two tests in 90 subjects employed at the Public Health Institute Ostrava who had previously undergone COVID-19 infection or were vaccinated against that disease. To the best of our knowledge, this is the first head-to-head comparison of these two tests evaluating T-cell-mediated immunity against SARS-CoV-2. In addition, we also evaluated humoral immunity in the same individuals using the in-house virus neutralization test and IgG ELISA assay. The evaluation yielded similar results for both IGRAs, with Quan-T-Cell appearing to be insignificantly (p = 0.08) more sensitive (all 90 individuals were at least borderline positive) than T-SPOT.COVID (negative results found in five patients). The overall qualitative (presence/absence of immune response) agreement of both tests with virus neutralization test and anti-S IgG was also excellent (close or equal to 100% in all subgroups, with the exception of unvaccinated Omicron convalescents, a large proportion of whom, i.e., four out of six subjects, were IgG negative while at least borderline positive for T-cell-mediated immunity measured by Quan-T). This implies that the evaluation of T-cell-mediated immunity is a more sensitive indicator of immune response than the evaluation of IgG seropositivity. This is true at least for unvaccinated patients with a history of being infected only by the Omicron variant, but also likely for other groups of patients.

Center for Health Research Faculty of Medicine University of Ostrava 70300 Ostrava Czech Republic

Department of Epidemiology and Public Health Faculty of Medicine University of Ostrava 70300 Ostrava Czech Republic

Institute for Experimental Immunology Affiliated to EUROIMMUN Medizinische Labordiagnostik AG 23560 Lübeck Germany

Institute of Laboratory Medicine Faculty of Medicine University of Ostrava 70300 Ostrava Czech Republic

Public Health Institute Ostrava 70200 Ostrava Czech Republic

Zobrazit více v PubMed

Rashidzadeh H., Danafar H., Rahimi H., Mozafari F., Salehiabar M., Rahmati M.A., Rahamooz-Haghighi S., Mousazadeh N., Mohammadi A., Ertas Y.N., et al. Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): Diagnosis, treatment, therapy and future perspectives. Nanomedicine. 2021;16:497–516. doi: 10.2217/nnm-2020-0441. PubMed DOI PMC

Wang Y., Grunewald M., Perlman S. Methods in Molecular Biology. Vol. 2203. Humana; New York, NY, USA: 2020. Coronaviruses: An Updated Overview of Their Replication and Pathogenesis; pp. 1–29. PubMed DOI PMC

Kuhn J.H., Li W., Choe H., Farzan M. What’s new in the renin-angiotensin system? CMLS Cell. Mol. Life Sci. 2004;61:2738–2743. doi: 10.1007/s00018-004-4242-5. PubMed DOI PMC

Hosseini A., Hashemi V., Shomali N., Asghari F., Gharibi T., Akbari M., Gholizadeh S., Jafari A. Innate and adaptive immune responses against coronavirus. Biomed Pharm. 2020;132:110859. doi: 10.1016/j.biopha.2020.110859. PubMed DOI PMC

Zmievskaya E., Valiullina A., Ganeeva I., Petukhov A., Rizvanov A., Bulatov E. Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections. Biomedicines. 2021;9:59. doi: 10.3390/biomedicines9010059. PubMed DOI PMC

Terreri S., Mortari E.P., Vinci M.R., Russo C., Alteri C., Albano C., Colavita F., Gramigna G., Agrati C., Linardos G., et al. Persistent B cell memory after SARS-CoV-2 vaccination is functional during breakthrough infections. Cell Host Microbe. 2022;30:400–408.e4. doi: 10.1016/j.chom.2022.01.003. PubMed DOI PMC

Primorac D., Brlek P., Matišić V., Molnar V., Vrdoljak K., Zadro R., Parčina M. Cellular Immunity—The Key to Long-Term Protection in Individuals Recovered from SARS-CoV-2 and after Vaccination. Vaccines. 2022;10:442. doi: 10.3390/vaccines10030442. PubMed DOI PMC

Noh J.Y., Jeong H.W., Shin E.-C. SARS-CoV-2 mutations, vaccines, and immunity: Implication of variants of concern. Signal Transduct. Target. Ther. 2021;6:203. doi: 10.1038/s41392-021-00623-2. PubMed DOI PMC

Tang F., Quan Y., Xin Z.-T., Wrammert J., Ma M.-J., Lv H., Wang T.-B., Yang H., Richardus J.H., Liu W., et al. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: A six-year follow-up study. J. Immunol. 2011;186:7264–7268. doi: 10.4049/jimmunol.0903490. PubMed DOI

Swadling L., Maini M.K. T cells in COVID-19—United in diversity. Nat. Immunol. 2020;21:1307–1308. doi: 10.1038/s41590-020-0798-y. PubMed DOI

Sette A., Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861–880. doi: 10.1016/j.cell.2021.01.007. PubMed DOI PMC

Moss P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 2022;23:186–193. doi: 10.1038/s41590-021-01122-w. PubMed DOI

Dhawan M., Rabaan A.A., Fawarah M.M.A., Almuthree S.A., Alsubki R.A., Alfaraj A.H., Mashraqi M.M., Alshamrani S.A., Abduljabbar W.A., Alwashmi A.S.S., et al. Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. Vaccines. 2023;11:101. doi: 10.3390/vaccines11010101. PubMed DOI PMC

Oh H.-L.J., Chia A., Chang C.X.L., Leong H.N., Ling K.L., Grotenbreg G.M., Gehring A.J., Tan Y.J., Bertoletti A. Engineering T Cells Specific for a Dominant Severe Acute Respiratory Syndrome Coronavirus CD8 T Cell Epitope. J. Virol. 2011;85:10464–10471. doi: 10.1128/JVI.05039-11. PubMed DOI PMC

Murugesan K., Jagannathan P., Pham T.D., Pandey S., Bonilla H.F., Jacobson K., Parsonnet J., Andrews J.R., Weiskopf D., Sette A., et al. Interferon-γ Release Assay for Accurate Detection of Severe Acute Respiratory Syndrome Coronavirus 2 T-Cell Response. Clin. Infect. Dis. 2021;73:e3130–e3132. doi: 10.1093/cid/ciaa1537. PubMed DOI PMC

Mouton W., Compagnon C., Saker K., Daniel S., Djebali S., Lacoux X., Pozzetto B., Oriol G., Laubreton D., Prieux M., et al. Specific detection of memory T-cells in COVID-19 patients using standardized whole-blood Interferon gammarelease assay. Eur. J. Immunol. 2021;51:3239–3242. doi: 10.1002/eji.202149296. PubMed DOI PMC

Masiá M., Fernández-González M., García J.A., Padilla S., García-Abellán J., Botella Á., Mascarell P., Agulló V., Gutiérrez F. Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade. EBioMedicine. 2022;82:104153. doi: 10.1016/j.ebiom.2022.104153. PubMed DOI PMC

Barreiro P., Sanz J.C., San Román J., Pérez-Abeledo M., Carretero M., Megías G., Viñuela-Prieto J.M., Ramos B., Canora J., Martínez-Peromingo F.J., et al. A Pilot Study for the Evaluation of an Interferon Gamma Release Assay (IGRA) To Measure T-Cell Immune Responses after SARS-CoV-2 Infection or Vaccination in a Unique Cloistered Cohort. J. Clin. Microbiol. 2022;60:e0219921. doi: 10.1128/jcm.02199-21. PubMed DOI PMC

Seraceni S., Zocca E., Cervone T.E., Tomassetti F., Polidori I., Valisi M., Broccolo F., Calugi G., Bernardini S., Pieri M. T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers. Diseases. 2022;10:49. doi: 10.3390/diseases10030049. PubMed DOI PMC

Zhao J., Wang L., Schank M., Dang X., Lu Z., Cao D., Khanal S., Nguyen L.N., Nguyen L.N.T., Zhang J., et al. SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects. Virus Res. 2021;304:198508. doi: 10.1016/j.virusres.2021.198508. PubMed DOI PMC

Guo L., Wang G., Wang Y., Zhang Q., Ren L., Gu X., Huang T., Zhong J., Wang Y., Wang X., et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: A longitudinal cohort study. Lancet Microbe. 2022;3:e348–e356. doi: 10.1016/S2666-5247(22)00036-2. PubMed DOI PMC

Kaaijk P., Pimentel V.O., Emmelot M.E., Poelen M.C.M., Cevirgel A., Schepp R.M., den Hartog G., Reukers D.F.M., Beckers L., van Beek J., et al. Children and Adults with Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months. Front. Immunol. 2022;13:817876. doi: 10.3389/fimmu.2022.817876. PubMed DOI PMC

Zuo J., Dowell A.C., Pearce H., Verma K., Long H.M., Begum J., Aiano F., Amin-Chowdhury Z., Hoschler K., Brooks T., et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat. Immunol. 2021;22:620–626. doi: 10.1038/s41590-021-00902-8. PubMed DOI PMC

Šimánek V., Pecen L., Krátká Z., Fürst T., Řezáčková H., Topolčan O., Fajfrlík K., Sedláček D., Šín R., Pazdiora P., et al. Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test. Diagnostics. 2021;11:593. doi: 10.3390/diagnostics11040593. PubMed DOI PMC

Homza M., Zelena H., Janosek J., Tomaskova H., Jezo E., Kloudova A., Mrazek J., Svagera Z., Prymula R. Covid-19 antigen testing: Better than we know? A test accuracy study. Infect. Dis. 2021;53:661–668. doi: 10.1080/23744235.2021.1914857. PubMed DOI PMC

Janošek J., Komárek A. Post-infection immunity provides excellent protection from COVID-19 ICU hospitalization during Delta and Omicron waves. Infect. Dis. 2022;55:74–77. doi: 10.1080/23744235.2022.2125575. PubMed DOI

Lindemann M., Klisanin V., Thümmler L., Fisenkci N., Tsachakis-Mück N., Ditschkowski M., Schwarzkopf S., Klump H., Reinhardt H.C., Horn P.A., et al. Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients. Vaccines. 2021;9:1075. doi: 10.3390/vaccines9101075. PubMed DOI PMC

Tassignon J., Burny W., Dahmani S., Zhou L., Stordeur P., Byl B., De Groote D. Monitoring of cellular responses after vaccination against tetanus toxoid: Comparison of the measurement of IFN-gamma production by ELISA, ELISPOT, flow cytometry and real-time PCR. J. Immunol. Methods. 2005;305:188–198. doi: 10.1016/j.jim.2005.07.014. PubMed DOI

Phillips E., Adele S., Malone T., Deeks A., Stafford L., Dobson S.L., Amini A., Skelly D., Eyre D., Jeffery K., et al. Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers. Clin. Exp. Immunol. 2022;209:90–98. doi: 10.1093/cei/uxac042. PubMed DOI PMC

Prendecki M., Clarke C., Edwards H., McIntyre S., Mortimer P., Gleeson S., Martin P., Thomson T., Randell P., Shah A., et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann. Rheum. Dis. 2021;80:1322–1329. doi: 10.1136/annrheumdis-2021-220626. PubMed DOI PMC

Angyal A., Longet S., Moore S.C., Payne R.P., Harding A., Tipton T., Rongkard P., Ali M., Hering L.M., Meardon N., et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: A multicentre prospective cohort study. Lancet Microbe. 2022;3:e21–e31. doi: 10.1016/S2666-5247(21)00275-5. PubMed DOI PMC

Schiavoni I., Olivetta E., Natalucci F., Olivieri G., Lo Presti A., Fedele G., Stefanelli P., Ceccarelli F., Conti F. Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab. Lupus. 2023 doi: 10.1177/09612033221151012. PubMed DOI PMC

Jordan S.C. Innate and adaptive immune responses to SARS-CoV-2 in humans: Relevance to acquired immunity and vaccine responses. Clin. Exp. Immunol. 2021;204:310–320. doi: 10.1111/cei.13582. PubMed DOI PMC

Cox M., Peacock T.P., Harvey W.T., Hughes J., Wright D.W., Willett B.J., Thomson E., Gupta R.K., Peacock S.J., Robertson D.L., et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat. Rev. Microbiol. 2022;21:112–124. doi: 10.1038/s41579-022-00809-7. PubMed DOI PMC

Gallais F., Velay A., Nazon C., Wendling M.-J., Partisani M., Sibilia J., Candon S., Fafi-Kremer S. Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France. Emerg. Infect. Dis. 2021;27:113–121. doi: 10.3201/eid2701.203611. PubMed DOI PMC

Goldberg Y., Mandel M., Bar-On Y.M., Bodenheimer O., Freedman L.S., Ash N., Alroy-Preis S., Huppert A., Milo R. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. N. Engl. J. Med. 2022;386:2201–2212. doi: 10.1056/NEJMoa2118946. PubMed DOI PMC

Altarawneh H.N., Chemaitelly H., Ayoub H.H., Tang P., Hasan M.R., Yassine H.M., Al-Khatib H.A., Smatti M.K., Coyle P., Al-Kanaani Z., et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N. Engl. J. Med. 2022;387:21–34. doi: 10.1056/NEJMoa2203965. PubMed DOI PMC

Kim T.-S., Shin E.-C. The activation of bystander CD8+ T cells and their roles in viral infection. Exp. Mol. Med. 2019;51:1–9. doi: 10.1038/s12276-019-0316-1. PubMed DOI PMC

Piler P., Thon V., Andrýsková L., Doležel K., Kostka D., Pavlík T., Dušek L., Pikhart H., Bobák M., Matic S., et al. Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population. Commun. Med. 2022;2:19. doi: 10.1038/s43856-022-00080-0. PubMed DOI PMC